Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IXT-003
- Development stage
- Preclinical
- Lead developer
- invoX Pharma
- Administration
- Inhalation
01
Overview
IXT-003 is an investigational inhalation therapy being developed by invoX Pharma for the treatment of Chronic Obstructive Pulmonary Disease (COPD). The drug is delivered via the proprietary Softhaler® platform, which is a dry powder inhalation (DPI) technology designed to optimize the delivery of medications to the lungs. The Softhaler device is engineered to be breath-actuated and to provide consistent dosing across a range of patient inspiratory flow rates. While IXT-003 is a key candidate in invoX Pharma's respiratory pipeline, specific details regarding its active pharmaceutical ingredient (API), molecular target, and exact mechanism of action have not been publicly disclosed by the developer as of early 2024.
Beyond the preview
Go deeper on IXT-003.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IXT-003.